Literature DB >> 27595697

Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.

Christian McNeely1, Stephen Markwell1, Christina M Vassileva2.   

Abstract

BACKGROUND: Since year 2000, reducing hospital readmissions has become a public health priority. In addition, there have been major changes in percutaneous coronary intervention (PCI) during this period.
METHODS: The cohort consisted of 3,250,194 patients admitted for PCI from January 2000 through November 2012.
RESULTS: Overall, 30-day readmission was 15.8%. Readmission rates declined from 16.1% in 2000 to 15.4% in 2012 (adjusted odds ratio for readmission 1.33 in 2000 compared with 2012). Of all readmissions after PCI, the majority were for cardiovascular-related conditions (>60%); however, only a small percentage (<8%) of total readmissions were for acute myocardial infarction, unstable angina, or cardiac arrest/cardiogenic shock. A much larger percentage of patients were readmitted with chest pain/angina (7.9%), chronic ischemic heart disease (26.6%), and heart failure (12%). A small proportion was due to procedural complications and gastrointestinal (GI) bleeding. The use of PCI with stenting during readmissions was variable, increasing from 14.2% in 2000 to 23.7% in 2006 and then declining to 12.1% in 2012. Hospital mortality during readmission was 2.5% overall and varied over time (2.8% in 2000, decreasing to 2.2% in 2006 and then rising again to 3.1% in 2012). Patients who were readmitted had >4× higher 30-day mortality than those who were not.
CONCLUSIONS: Among Medicare beneficiaries, readmission after PCI declined over time despite patients having more comorbidities. This translated into a 33% lower likelihood of readmission in 2012 compared with 2000. A small proportion of readmissions were for acute coronary syndromes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27595697     DOI: 10.1016/j.ahj.2016.07.002

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.

Authors:  S Harada; Y Zhou; S Duncan; A R Armstead; G M Coshatt; C Dillon; B C Brott; J Willig; J A Alsip; W B Hillegass; N A Limdi
Journal:  Clin Pharmacol Ther       Date:  2017-06-01       Impact factor: 6.875

2.  Should We Care About Short-Term Readmissions After Percutaneous Coronary Intervention?

Authors:  Jordan B Strom; Robert W Yeh
Journal:  Circ Cardiovasc Interv       Date:  2017-12       Impact factor: 6.546

3.  Etiologies and predictors of 30-day readmissions in patients undergoing percutaneous mechanical circulatory support-assisted percutaneous coronary intervention in the United States: Insights from the Nationwide Readmissions Database.

Authors:  Chirag Bavishi; Alejandro Lemor; Vrinda Trivedi; Saurav Chatterjee; Pedro Moreno; John Lasala; Herbert D Aronow; J Dawn Abbott
Journal:  Clin Cardiol       Date:  2018-04-26       Impact factor: 2.882

4.  LncRNA UCA1, miR-26a, and miR-195 in coronary heart disease patients: Correlation with stenosis degree, cholesterol levels, inflammatory cytokines, and cell adhesion molecules.

Authors:  Jie Li; Zhisong Chen; Xiaoyan Wang; Haoming Song
Journal:  J Clin Lab Anal       Date:  2021-12-01       Impact factor: 2.352

5.  Impact of the Malnutrition on Mortality in Elderly Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Liling Chen; Zhidong Huang; Jin Lu; Yanfang Yang; Yuxiong Pan; Kunming Bao; Junjie Wang; Weihua Chen; Jin Liu; Yong Liu; Kaihong Chen; Weiguo Li; Shiqun Chen
Journal:  Clin Interv Aging       Date:  2021-07-14       Impact factor: 4.458

6.  Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy.

Authors:  Mahesh K Vidula; Cian P McCarthy; Neel M Butala; Kevin F Kennedy; Jason H Wasfy; Robert W Yeh; Eric A Secemsky
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.